FLEXIQuant-LF to quantify protein modification extent in label-free proteomics data.

PTM identification PTM quantification biochemistry chemical biology computational biology human label-free quantification mass spectrometry modification stoichiometry peptide modification systems biology

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
07 12 2020
Historique:
received: 11 05 2020
accepted: 23 11 2020
entrez: 7 12 2020
pubmed: 8 12 2020
medline: 2 4 2021
Statut: epublish

Résumé

Improvements in LC-MS/MS methods and technology have enabled the identification of thousands of modified peptides in a single experiment. However, protein regulation by post-translational modifications (PTMs) is not binary, making methods to quantify the modification extent crucial to understanding the role of PTMs. Here, we introduce FLEXIQuant-LF, a software tool for large-scale identification of differentially modified peptides and quantification of their modification extent without knowledge of the types of modifications involved. We developed FLEXIQuant-LF using label-free quantification of unmodified peptides and robust linear regression to quantify the modification extent of peptides. As proof of concept, we applied FLEXIQuant-LF to data-independent-acquisition (DIA) data of the anaphase promoting complex/cyclosome (APC/C) during mitosis. The unbiased FLEXIQuant-LF approach to assess the modification extent in quantitative proteomics data provides a better understanding of the function and regulation of PTMs. The software is available at https://github.com/SteenOmicsLab/FLEXIQuantLF.

Identifiants

pubmed: 33284109
doi: 10.7554/eLife.58783
pii: 58783
pmc: PMC7721442
doi:
pii:

Substances chimiques

Peptides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : S10 OD010700
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124284
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI099204
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196703
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM112007
Pays : United States
Organisme : NIGMS NIH HHS
ID : RC4 GM096319
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS066973
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090255
Pays : United States
Organisme : Deutsche Forschungsgemeinschaft
ID : RE3474/2-2
Pays : International

Informations de copyright

© 2020, Schlaffner et al.

Déclaration de conflit d'intérêts

CS, KK, JM, RC, BR, JS, HS No competing interests declared

Références

Anal Chem. 2016 Apr 5;88(7):3704-14
pubmed: 26877193
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20
pubmed: 25514926
Mol Cell Proteomics. 2014 Jan;13(1):311-28
pubmed: 24173317
Cell Rep. 2014 Sep 11;8(5):1583-94
pubmed: 25159151
Proteomics. 2004 Jun;4(6):1551-61
pubmed: 15174125
Nat Methods. 2012 Apr 08;9(5):504-8
pubmed: 22484849
Mol Syst Biol. 2011 Nov 08;7:549
pubmed: 22068332
Cell. 2012 Jun 22;149(7):1565-77
pubmed: 22726442
Mol Cell Proteomics. 2011 Oct;10(10):M110.006452
pubmed: 21715320
Mol Cell Proteomics. 2017 Dec;16(12):2296-2309
pubmed: 29070702
Anal Chem. 2004 Jul 15;76(14):3935-43
pubmed: 15253627
Proteomics. 2002 Sep;2(9):1267-76
pubmed: 12362345
Nat Biotechnol. 2019 Apr;37(4):469-479
pubmed: 30936560
EMBO J. 2014 Feb 18;33(4):385-99
pubmed: 24510915
Nat Methods. 2017 May;14(5):513-520
pubmed: 28394336
Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50
pubmed: 25053359
Mol Cell Proteomics. 2013 Mar;12(3):825-31
pubmed: 23266961
Cell Rep. 2018 Jun 19;23(12):3685-3697.e4
pubmed: 29925008
Nat Commun. 2012 Jun 06;3:876
pubmed: 22673903
Mol Cell Proteomics. 2015 May;14(5):1400-10
pubmed: 25724911
Proteomics. 2012 Apr;12(8):1111-21
pubmed: 22577012
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Sci Signal. 2013 Jun 04;6(278):rs11
pubmed: 23737553
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6069-74
pubmed: 18420821
J Proteome Res. 2018 May 4;17(5):1844-1851
pubmed: 29578715
Mol Cell Proteomics. 2012 Jun;11(6):O111.016717
pubmed: 22261725
Mol Cell. 2011 Oct 21;44(2):325-40
pubmed: 21906983
Annu Rev Biochem. 1981;50:783-814
pubmed: 6791580
ACS Chem Biol. 2010 Jan 15;5(1):105-19
pubmed: 20047291
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6940-5
pubmed: 12771378
Nat Biotechnol. 2005 Jan;23(1):94-101
pubmed: 15592455
Philos Trans R Soc Lond B Biol Sci. 1999 Sep 29;354(1389):1583-90
pubmed: 10582244
J Proteome Res. 2009 May;8(5):2201-10
pubmed: 19344176
Nat Methods. 2011 Jul 03;8(8):677-83
pubmed: 21725298
Methods Mol Biol. 2012;893:295-319
pubmed: 22665308

Auteurs

Christoph N Schlaffner (CN)

F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.
Department of Neurology, Harvard Medical School, Boston, United States.

Konstantin Kahnert (K)

Department of Pathology, Boston Children's Hospital, Boston, United States.
Bioinformatics Unit (MF1), Robert Koch Institute, Berlin, Germany.
Department of Medical Biotechnology, Institute of Biotechnology, Technische Universität Berlin, Berlin, Germany.

Jan Muntel (J)

Department of Pathology, Boston Children's Hospital, Boston, United States.
Department of Pathology, Harvard Medical School, Boston, United States.

Ruchi Chauhan (R)

F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.

Bernhard Y Renard (BY)

Bioinformatics Unit (MF1), Robert Koch Institute, Berlin, Germany.
Data Analytics and Computational Statistics, Hasso-Plattner-Institute, Faculty of Digital Engineering, University of Potsdam, Potsdam, Germany.

Judith A Steen (JA)

F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States.
Department of Neurology, Harvard Medical School, Boston, United States.

Hanno Steen (H)

Department of Pathology, Boston Children's Hospital, Boston, United States.
Department of Pathology, Harvard Medical School, Boston, United States.
Precision Vaccines Program, Boston Children's Hospital, Boston, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH